Comparative Pharmacology
Head-to-head clinical analysis: CEFOTAXIME SODIUM versus KAFOCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFOTAXIME SODIUM versus KAFOCIN.
CEFOTAXIME SODIUM vs KAFOCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefotaxime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP-1A and PBP-3, leading to cell lysis and death.
KAFOCIN (cefepime/enmetazobactam) is a combination of a fourth-generation cephalosporin (cefepime) and a β-lactamase inhibitor (enmetazobactam). Enmetazobactam inhibits extended-spectrum β-lactamases (ESBLs) and other class A β-lactamases, restoring cefepime's activity against β-lactamase-producing bacteria. Cefepime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell death.
1-2 g IV/IM every 8 hours; maximum 12 g/day for severe infections.
1 g IV every 8 hours.
None Documented
None Documented
Terminal elimination half-life is 0.9-1.5 hours in adults with normal renal function; prolonged to 2.5-10 hours in renal impairment (CrCl <20 mL/min). In neonates, half-life is 3-6 hours.
Terminal elimination half-life: 4.5-6.5 hours (increased to 12-18 hours in severe renal impairment; CrCl <30 mL/min).
Renal (50-60% unchanged), biliary (5-10%), with approximately 20-30% metabolized to desacetylcefotaxime (also renally eliminated). Total renal elimination of parent drug and metabolite accounts for >80%.
Renal: 60-80% unchanged; biliary/fecal: 15-30% as metabolites; total clearance ~120 mL/min.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic